Compare Hyperliquid Strategies Inc Common Stock (PURR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyperliquid Strategies Inc Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Hyperliquid Strategies Inc Common Stock trades at $9.31 (market cap $2.02B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.4× Hyperliquid Strategies Inc Common Stock's market cap, and Hyperliquid Strategies Inc Common Stock is more actively traded (9,119,303 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Hyperliquid Strategies Inc Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PURR | TVTX | |
|---|---|---|
Market Cap | $2.02B | $4.88B |
Volume | 9,119,303 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $14.09 | $67.52 |
52-Week Low | $3.10 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.88B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PURR trades at $10.23, down 1.63% over 24 hours, with a bullish technical signal despite recent weakness. The stock shows extreme profitability with a net income margin of 3,229.83% and has beaten earnings estimates for three consecutive quarters. Recent news highlights institutional activity and positive analyst coverage, with a consensus price target of $19.80 implying significant upside.
The outlook is positive given strong earnings momentum and unanimous analyst buy ratings, but risks include high revenue concentration and potential volatility from its asset-heavy business model. The stock's low P/E ratio of 3.18 suggests undervaluation if profitability sustains.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyperliquid Strategies Inc Common Stock
Hyperliquid Strategies is a digital asset treasury company focused on managing a treasury of HYPE tokens, the native digital assets of the Hyperliquid Layer-1 blockchain.
Read more on PURR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
